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Violacein is a violet pigment extracted from the gram-negative bacterium Chromobacterium violaceum. It
presents bactericidal, tumoricidal, trypanocidal, and antileishmanial activities. We show that micromolar
concentrations efficiently killed chloroquine-sensitive and -resistant Plasmodium falciparum strains in vitro;
inhibited parasitemia in vivo, even after parasite establishment; and protected Plasmodium chabaudi chabaudi-
infected mice from a lethal challenge.
Violacein is a violet pigment isolated from Chromobacterium
violaceum, a gram-negative betaproteobacterium found in the
Amazon River in Brazil. It has been reported to kill bacteria
(4) and induces apoptosis in various types of cancer cells (1, 5,
7, 8, 10, 11). Moderate activity against Trypanosoma cruzi and
Leishmania amazonensis promastigotes has also been observed
(3, 9). Due to the widespread presence of drug resistance in the
malaria parasite, resulting in dramatically decreased efficacy of
available antimalarial drugs (15), and the fact that immuno-
protection achieved by the most successful malaria vaccine is
only partial and short-lived (14), we evaluated the in vitro and
in vivo effects of violacein on human and murine blood stage
forms of Plasmodium parasites.
Isolation and purification of violacein, 3-[1,2-dihydro-5-(5-hy-
droxy-1H-indol-3-yl)-2-oxo-3H-pyrrol-3-ilydeno]-1,3-dihydro-2H-
indol-2-one (Fig. 1), from C. violaceum (CCT3496) were per-
formed as previously described (12). Toxicity was measured as
the concentration-dependent lysis of normal erythrocytes (NE)
by counting red blood cells per milliliter with the aid of a
Neubauer chamber. After 48 h of exposure to various concen-
trations of violacein, the percent red blood cell density
(RBCD) relative to that of the control (without violacein) was
monitored and calculated according to the formula (RBCD
per milliliter in the presence of violacein/RBCD per milliliter
without violacein)  100. As shown in Fig. 2A, a slight reduc-
tion in the RBCD percentage at violacein concentrations of
8.0 M was observed. Significant (Mann-Whitney U test, P
0.05) toxicity to NE occurred at a concentration of 14.0 M.
Next, we performed dose-response assays to obtain the 50%
inhibitory concentrations (IC50s) of violacein against erythro-
cytes infected with chloroquine-sensitive or -resistant strains of
P. falciparum (3D7 [16] or S20 [2], respectively) at 1% para-
sitemia and a 2% final hematocrit. We used [3H]hypoxanthine
(Amersham Biosciences, Amersham, United Kingdom) incor-
poration to assess parasite growth according to a protocol
described elsewhere (13). Violacein was tested in triplicate at
least three times with different batches and cells, and parasite
growth was compared to that in nontreated infected erythro-
cytes (IE), which represented 100% parasite growth. Percent
parasite growth inhibition was calculated according to the for-
mula [1  (cpm of treated IE  cpm of NE/cpm of nontreated
IE  cpm of NE)]  100. After a 48-h incubation, violacein
inhibited parasite development even at the lowest tested con-
centration of 0.06 M and completely abrogated parasite via-
bility at concentrations of 1.0 M (Fig. 2B).
The IC50 of violacein against P. falciparum strain 3D7 was
calculated as 0.85  0.11 M. We then tested whether the
effect of violacein was directed against young (rings, 0 to 24 h)
or mature (trophozoites and schizonts, 24 to 48 h) blood forms
by using synchronized parasites ( 6 h) obtained by repeated
5% sorbitol treatment as previously described (6). After a 24-h
incubation, inhibition of the different parasite stages by viola-
cein was measured. As shown in Fig. 2C, there was no statis-
tically significant difference (Mann-Whitney U test, P  0.05)
between the inhibitory values of violacein in either parasite
stage. We then asked if susceptibility or resistance to chloro-
quine also predicts parasite sensitivity to violacein. As shown in
Fig. 2D, the violacein IC50s for strains 3D7 and S20 did not
differ significantly (0.85  0.11 and 0.63  0.13 M, respec-
tively; Mann-Whitney U test, P  0.05).
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We then investigated whether violacein antimalarial activity
could be sustained in a mouse model, where other character-
istics such as bioavailability and pharmacokinetics have to be
taken in account. For the in vivo assays, C57BL/6 mice (7 to 10
mice per group, aged 7 to 10 weeks, and with a body weight of
20  3 g) were infected with a nonlethal (AS) or a lethal (AJ)
strain of Plasmodium chabaudi chabaudi by intraperitoneal
(i.p.) injection with 106 IE. Parasitemia levels were determined
daily by counting the IE among at least 1,000 erythrocytes in
Giemsa-stained blood smears. As shown in Fig. 3A, daily ad-
ministration of violacein i.p. for 11 consecutive days (0 to 10
days postinfection [p.i.]) reduced the parasitemia of P.
chabaudi chabaudi AS-infected mice. Thirty-nine percent in-
hibition was observed on day 7 p.i. (parasitemia peak), in
comparison to nontreated mice (control; Table 1), even at a
low dose of 0.75 mg/kg/day. Moreover, the two highest doses of
violacein (3.75 and 7.5 mg/kg/day) almost completely abolished
parasitemia on day 7 p.i., corresponding, respectively, to 82
and 87% inhibition of parasite development (Table 1). In ad-
dition, violacein doses of 0.75 to 7.5 mg/kg/day were able to
inhibit the peak parasitemia in a dose-dependent manner (Ta-
ble 1).
Since violacein did not completely abrogate parasitemia
early in infection and drug pressure was removed by day 10 p.i.,
we monitored the parasitemia levels of P. chabaudi chabaudi
AS-infected mice treated with the highest dose of violacein
daily until day 22 p.i. Notably, on day 16 p.i., which represents
the sixth day after the end of violacein treatment, parasite
development was still significantly (Mann-Whitney U test, P 
FIG. 1. Chemical structure of violacein.
FIG. 2. Evaluation of violacein antimalarial activity against P. falciparum. (A) Noninfected erythrocytes (RBC) were cultivated for 48 h at 37°C
in the presence of different concentrations of violacein. The RBCD was determined as a percentage of that the control (without drug). Inhibition
of the growth of P. falciparum 3D7 IE cultivated for 48 h at 37°C with different concentrations of violacein (B) and of young or mature stages of
this parasite (C) is also shown. (D) Effect of violacein against a chloroquine-resistant strain (S20) of P. falciparum in IE. Results are expressed as
the mean of triplicate measurements  the standard deviation.
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0.05) inhibited (up to 59%; Fig. 3B). To verify whether viola-
cein had an effect on parasite growth after the establishment of
infection, P. chabaudi chabaudi AS-infected mice received vio-
lacein from day 5 (16% parasitemia) to day 10 p.i. This can
reflect the time point when malaria therapy is given to patients.
As shown in Fig. 3C, violacein administration during patent
parasitemia was able to reduce parasite growth significantly
(Mann-Whitney U test, P  0.01), by up to 50.1%, in compar-
FIG. 3. Effect of violacein on mouse-derived Plasmodium parasites. Groups of 7 to 10 C57BL/6 mice were infected i.p. with 106 P. chabaudi
chabaudi AS IE and then left untreated or treated with different doses of violacein administered i.p. for 11 consecutive days (days 0 to 10 p.i.),
starting on day 0 at 1 h p.i. Parasitemia levels were determined daily until day 12 p.i. (A) or up to day 22 p.i. (B) after treatment with the highest
dose (7.5 mg/kg/day). (C) Analysis of violacein antimalarial activity after parasite establishment and treatment for 6 consecutive days (days 5 to
10 p.i.) with the highest dose of violacein in P. chabaudi chabaudi AS-infected mice. Results are expressed as the mean of a group of mice  the
standard deviation. (D) Analysis of the survival of groups of 10 C57BL/6 mice infected with P. chabaudi chabaudi AJ (lethal strain) by i.p. injection
of 106 IE and then treated i.p. with violacein at 7.5 mg/kg/day for 11 consecutive days (days 0 to 10 p.i.). The drug administration period is indicated
by shading in each graph.
TABLE 1. Inhibition of parasitemia in P. chabaudi chabaudi AS-infected mice under violacein treatment
Violacein dose
(mg/kg/day)
Mean % inhibitiona  SD (P value)
Day 5 Day 6 Day 7 Day 8
7.5 56.48 12.84 (0.005) 75.40 5.17 (0.005) 86.90 3.53 (0.005) 84.67 5.43 (0.05)
3.75 33.23 14.72 (NS)b 64.89  8.00 (0.005) 82.12 4.33 (0.005) 75.73 13.93 (0.05)
0.75 3.58 33.80 (NS) 20.42 36.30 (NS) 39.25 14.15 (0.05) 48.85 15.08 (NS)
0.075 NIc (ND)d NI (ND) NI (ND) 12.04 6.11 (NS)
a The data shown are percentages of the parasitemia of nontreated mice, which was defined as 100%. Values for groups of 7 to 10 mice are shown.
b NS, not statistically significant.
c NI, no inhibition.
d ND, not determined.
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ison to nontreated animals on the seventh day of infection.
Next, to determine the protective effect of violacein, mice were
infected with the lethal AJ strain of P. chabaudi chabaudi and
their survival rate was evaluated. As shown in Fig. 3D, 100% of
the nontreated mice died by day 10 p.i., with 50% of the deaths
occurring early on day 7 p.i. In contrast, animals treated with
violacein at 7.5 mg/kg/day did not succumb to infection until
days 9 (10%) and 14 (10%) p.i., reaching 80% survival on day
16; clearly demonstrating the significant (log rank test, P 
0.0001) protective effect of violacein.
This study demonstrates for the first time the antimalarial
activity of violacein by showing inhibition of the growth of
human- and mouse-derived Plasmodium parasites. Also, viola-
cein was effective against young and mature forms of the hu-
man parasite and its activity extended to chloroquine-sensitive
and -resistant strains of P. falciparum. Our data call for new
formulations based on violacein nanoparticles to improve
solubility, bioavailability, and activity and to decrease drug
toxicity.
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